Sonia Pascual

Mrs. Sonia Pascual


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2024 in Medicina Clinica
Verified
Journal Article
Closed access
SPSonia Pascual
Sonia Pascual
AHAna Castell Herrera
Ana Castell Herrera
JPJuan Julian Cuesta Pérez
Juan Julian Cuesta Pérez
APAdriana Rodriguez Perojo
Adriana Rodriguez Perojo
AFAraceli Abad Fernández
Araceli Abad Fernández
MRMaria Teresa Río Ramirez
Maria Teresa Río Ramirez

9 September 2023 in European Respiratory Journal
Verified
Conference Paper
Closed access
SPSonia Pascual
Sonia Pascual
CLCristina Matesanz López
Cristina Matesanz López
BNBeatriz De Olaiz Navarro
Beatriz De Olaiz Navarro
JGJose Antonio Aramburu González
Jose Antonio Aramburu González
EREva Aguilar Rivilla
Eva Aguilar Rivilla
MRMaria Teresa Río Ramirez
Maria Teresa Río Ramirez
Introduction: Surgical lung biopsy (SLB) can be a useful tool in the diagnosis of interstitial lung disease (ILD). The aim of this study is to describe the diagnostic yield, complications and survival of SLB performed in our centre. Material and methods: Retrospective descriptive study of SLB performed from January 2014 to October 2022. We describe the clinical characteristics, diagnostic results and survival after SLB. Presented as mean and standard deviation. Results: SLB was performed on 51 patients. The general characteristics, comorbidities of the patients, initial pre-surgical clinical suspicion and final histological diagnosis are shown in figure 1. Post-surgical complications in 8 (15%): pneumonia 1 (2%),persistent air leak 2 (4%), mild wound infection 2 (4%), chronic pain 3 (6%), cardiovascular complication 1 (2%). There were no exacerbations of ILD in the following 3 months, no complicated pleural effusion and no respiratory failure. SLB conditioned some change in management in 36 cases (71%):corticosteroids were added in 10 (20%) and antifibrotics in 26 (51%). Overall survival at 1, 6 and 12 months after SLB was 98%,94% and 90% respectively. Conclusions: In our series of patients with ILD, SLB is a technique that provides diagnostic and therapeutic optimization in up to 71% of cases. Complications of surgery are minimal, mild, with a very low risk of mortality associated with the technique and no apparent risk of exacerbations.

12 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CLCristina Matesanz López
Cristina Matesanz López
CPCelia Pinedo-Sierra
Celia Pinedo-Sierra
JBJosé Manuel Padilla Brito
José Manuel Padilla Brito
SPSonia Pascual
Sonia Pascual
ERElizabeth Manuely González Revilla
Elizabeth Manuely González Revilla
MBMaría Asunción Nieto Barbero
María Asunción Nieto Barbero
Drug-induced sarcoid-like reactions (DISRs) are uncommon granulomatous disorders that develop in temporal association with drug exposure and closely resemble sarcoidosis clinically, radiologically, and histologically. Their recognition has become increasingly relevant with the expanding use of immune-modulating and targeted therapies. Immune checkpoint inhibitors and tumor necrosis factor-alpha inhibitors are among the best-documented causes, while sarcoid-like reactions have also been reported with interferons, dupilumab, BRAF/MEK inhibitors, and other biologic and targeted agents. Thoracic involvement is particularly common and typically manifests as bilateral hilar or mediastinal lymphadenopathy, with or without pulmonary parenchymal abnormalities. In patients with cancer, these findings may mimic disease progression and lead to inappropriate modification of effective anticancer therapy. Imaging findings are not specific, and histological confirmation may therefore be necessary when the differential diagnosis would alter clinical management. Management should be individualized according to clinical severity, organ involvement, diagnostic certainty, and the importance of continuing the suspected drug. Observation or continuation of therapy may be appropriate in selected asymptomatic or limited cases, whereas drug withdrawal and systemic corticosteroids may be required in symptomatic or multisystem disease. This narrative review summarizes current evidence on DISRs, with particular emphasis on pulmonary and intrathoracic manifestations, associated drug classes, diagnostic challenges, management, and outcomes. A respiratory-focused diagnostic pathway is proposed, integrating comparison with prior imaging, targeted microbiological sampling, selective bronchoscopic or other tissue biopsy, and assessment of competing diagnoses, including malignancy and immune checkpoint inhibitor pneumonitis. The pathway also supports individualized decisions on observation, drug continuation, or withdrawal; it is not a validated diagnostic instrument.